Integ. Proteins

What does Integ. Proteins do?

Integrated Proteins Ltd processes oil seeds in the Edible Oil industry and has a market cap of Rs 16 Cr. As of March 2025, it reported net sales of 21 Cr and a net profit of 0 Cr, with a P/E ratio of 16.00.

Overview: <BR>Integrated Proteins Ltd is engaged in the processing of various oil seeds and operates within the Edible Oil industry, categorized as a Micro Cap company.<BR><BR>History: <BR>Integrated Proteins Limited was incorporated as a public limited company in October 1992. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Net Sales: 21 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market cap: Rs 16 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 16.00 <BR>Industry P/E: 24 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.01 <BR>Return on Equity: 9.58% <BR>Price to Book: 6.24<BR><BR>Contact Details: <BR>Address: City Point Opp Town Hall, Station Road Jamnagar Gujarat : 361008 <BR>Tel: 91-288-2551901/902/903 <BR>Email: ps@arcadia.co.in <BR>Website: http://www.integratedproteins.com

Has Integ. Proteins declared dividend?

No Dividend History Available

Who are the peers of the Integ. Proteins?

Peers of Integ. Proteins include Marico, Patanjali Foods, AWL Agri Business, Gokul Agro, and others. Marico shows excellent management and capital structure, while Integ. Proteins has average growth and a 1-year return of 129.69%.

Peers: The peers of Integ. Proteins are Marico, Patanjali Foods, AWL Agri Busine., Gokul Agro, Sundrop Brands, CIAN Agro, Natraj Proteins, Ashiana Agro Ind, and Signature Green.<BR><BR>Quality Snapshot: Excellent management risk is observed at Marico, while Average management risk is found at Patanjali Foods and Gokul Agro, and the rest have Below Average management risk. Growth is Excellent at Patanjali Foods and Gokul Agro, Good at AWL Agri Busine. and CIAN Agro, while Average growth is seen at Integ. Proteins, and the rest have Below Average growth. Excellent capital structure is noted at Marico and Sundrop Brands, Good at Patanjali Foods, AWL Agri Busine., and Gokul Agro, while Integ. Proteins and the rest have Below Average or do not qualify.<BR><BR>Return Snapshot: CIAN Agro has the highest 1-year return at 1037.81%, while AWL Agri Busine. has the lowest at -27.15%. Integ. Proteins has a 1-year return of 129.69%, which is significantly higher than AWL Agri Busine. Additionally, the six-month return is negative for AWL Agri Busine., Gokul Agro, Ashiana Agro Ind, and Integ. Proteins.

What is the technical trend for Integ. Proteins?

As of June 4, 2025, Integ. Proteins shows a mildly bearish trend, with bearish weekly MACD and moving averages, despite mixed signals from the monthly indicators.

As of 4 June 2025, the technical trend for Integ. Proteins has changed from does not qualify to mildly bearish. The weekly MACD is bearish, while the monthly MACD is mildly bearish, indicating a weakening momentum. The daily moving averages are also bearish, reinforcing the negative sentiment. The Bollinger Bands show a mildly bearish stance on the weekly chart, contrasting with a bullish outlook on the monthly chart. The KST is bearish on the weekly timeframe but bullish monthly, suggesting mixed signals. Overall, the current technical stance is mildly bearish, driven primarily by the bearish indicators on the MACD and moving averages.

Who are in the management team of Integ. Proteins?

As of March 2023, the management team of Integ. Proteins includes Vinod P Mehta (Chairman), Arvindbhai Kantilal Shah (Managing Director), Piyush Chimanalal Vora (CFO), and several independent and non-executive directors. They oversee the company's strategic direction and operations.

As of March 2023, the management team of Integ. Proteins includes the following individuals:<BR><BR>1. Vinod P Mehta - Chairman (Non-Executive) & Director (Non-Independent)<BR>2. Arvindbhai Kantilal Shah - Executive Director & Managing Director<BR>3. Piyush Chimanalal Vora - Executive Director & Chief Financial Officer<BR>4. Bhalchandra Vyas - Independent Non-Executive Director<BR>5. Vijaykumar Shamjibhai Dattani - Independent Non-Executive Director<BR>6. Neepa Praful Kothari - Non-Executive & Non-Independent Director<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Who are the top shareholders of the Integ. Proteins?

The top shareholders of Integ. Proteins include Siddheshwar Advisory Private Limited with 23.89%, and promoter Vinod Prabhulal Mehta with 10.06%. Individual investors collectively hold 47.19%, with no institutional holdings or pledged shares reported.

The top shareholders of Integ. Proteins include Siddheshwar Advisory Private Limited, which holds the largest public share at 23.89%. The promoter with the highest individual holding is Vinod Prabhulal Mehta, who owns 10.06%. Additionally, individual investors collectively hold 47.19% of the company. There are no institutional holdings or pledged promoter shares reported.

How big is Integ. Proteins?

As of 21st July, Integrated Proteins Ltd has a market capitalization of 17.00 Cr, with net sales of 21.50 Cr and a net profit of 0.25 Cr in the latest four quarters. Specific values for Shareholder's Funds and Total Assets are unavailable.

As of 21st July, Integrated Proteins Ltd has a market capitalization of 17.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported net sales of 21.50 Cr and a net profit of 0.25 Cr.<BR><BR>The reporting period for the balance sheet data is the latest annual period, but specific values for Shareholder's Funds and Total Assets are unavailable.

How has been the historical performance of Integ. Proteins?

Integ. Proteins has shown significant growth, with net sales reaching 21.50 Cr in March 2025, up from 0.24 Cr in March 2024. The company also reported increased operating profit, profit before tax, and profit after tax, alongside a rise in earnings per share to 0.71.

Answer:<BR>The historical performance of Integ. Proteins shows significant growth in net sales, reaching 21.50 Cr in March 2025, up from just 0.24 Cr in March 2024 and 0.17 Cr in March 2023. The total operating income also increased to 21.50 Cr in March 2025, compared to 0.24 Cr in the previous year. The company has seen a notable rise in operating profit, which stood at 0.34 Cr in March 2025, a substantial improvement from 0.14 Cr in March 2024. Profit before tax also increased to 0.32 Cr in March 2025, up from 0.10 Cr in March 2024, while profit after tax reached 0.25 Cr, compared to 0.09 Cr in the prior year. The earnings per share (EPS) rose to 0.71 in March 2025 from 0.26 in March 2024, reflecting a positive trend in profitability.<BR><BR>Breakdown:<BR>Integ. Proteins has demonstrated a remarkable upward trajectory in its financial performance over the past few years. Starting from no sales in previous years, the company achieved net sales of 21.50 Cr in March 2025, marking a significant increase from 0.24 Cr in March 2024. This growth is mirrored in the total operating income, which also reached 21.50 Cr in March 2025. The operating profit has turned positive, with a reported 0.34 Cr in March 2025, compared to a loss of 0.11 Cr in March 2024. Profit before tax and profit after tax have both shown substantial increases, reaching 0.32 Cr and 0.25 Cr respectively in March 2025, indicating improved profitability. The earnings per share have also risen to 0.71, reflecting the company's enhanced financial health. Overall, Integ. Proteins has transitioned from a period of minimal activity to a phase of significant growth and profitability.

Is Integ. Proteins overvalued or undervalued?

As of November 27, 2025, Integ. Proteins is considered undervalued with an attractive investment appeal, reflected in its favorable PE ratio of 42.60 and EV to EBITDA of 14.06, despite a year-to-date return of -49.13%, while showing a strong three-year return of 97.78%.

As of 27 November 2025, the valuation grade for Integ. Proteins has moved from risky to attractive, indicating a significant improvement in its investment appeal. The company is currently considered undervalued. Key ratios include a PE ratio of 42.60, an EV to EBITDA of 14.06, and a PEG ratio of 0.11, which suggests that the stock is priced favorably relative to its growth potential.<BR><BR>In comparison to its peers, Integ. Proteins has a higher PE ratio than CIAN Agro, which stands at 33.9, but lower than Manorama Industries at 43.54. The EV to EBITDA ratio of Integ. Proteins is also more favorable than that of Manorama Industries, which is 28.15. Despite the recent underperformance in the stock's year-to-date return of -49.13% compared to the Sensex's 9.70%, the long-term performance over three years shows a remarkable return of 97.78%, reinforcing the potential for recovery and growth in value.

When is the next results date for Integrated Proteins Ltd?

The next results date for Integrated Proteins Ltd is 12 February 2026.

The next results date for Integrated Proteins Ltd is scheduled for 12 February 2026.

Are Integrated Proteins Ltd latest results good or bad?

Integrated Proteins Ltd's latest results are concerning, showing zero net sales and a net loss of ₹0.02 crores in Q3 FY26, indicating significant operational challenges and a lack of investor confidence. The stock has declined by 56.11% over the past year, reflecting poor performance compared to the broader market.

Integrated Proteins Ltd's latest results are concerning and indicate significant operational challenges. In the third quarter of FY26, the company reported zero net sales, a drastic decline from ₹4.20 crores in the previous quarter, marking a 100% quarter-on-quarter drop. This operational cessation is alarming, especially since the company had shown some activity in the prior quarter.<BR><BR>Additionally, Integrated Proteins recorded a net loss of ₹0.02 crores, compared to a profit of ₹0.05 crores in Q2 FY26. The company's return on equity is extremely low at just 1.51%, highlighting poor capital efficiency. Over the past year, the stock has declined by 56.11%, significantly underperforming the broader market, which has seen positive returns.<BR><BR>The lack of institutional support is another red flag, with zero holdings from foreign institutional investors, mutual funds, and insurance companies, and promoter holding has plummeted to just 2.23%. This suggests a lack of confidence in the company's future prospects.<BR><BR>Overall, the latest results reflect a troubling situation for Integrated Proteins, with multiple indicators pointing to operational instability and a challenging path ahead for recovery.

Should I buy, sell or hold Integrated Proteins Ltd?

Why is Integrated Proteins Ltd falling/rising?

As of 31-Mar, Integrated Proteins Ltd's stock price is rising to Rs. 72.75, reflecting a significant increase of 111.48% year-to-date, outperforming the Sensex. Despite concerns over decreased promoter holding and delivery volume, the stock's strong momentum and recent performance indicate robust investor interest.

As of 31-Mar, Integrated Proteins Ltd's stock price is rising, currently at Rs. 72.75, reflecting an increase of 1.42 (1.99%). This upward movement is supported by several key factors. The stock has experienced a remarkable performance over the past week, gaining 11.26%, and an impressive 85.16% over the past month. Year-to-date, the stock has surged by 111.48%, significantly outperforming the Sensex, which has declined by 15.57% during the same period.<BR><BR>Today's performance is particularly noteworthy as the stock has hit a new 52-week high of Rs. 72.75 and has outperformed its sector by 5.85%. The stock has been on a consecutive gain streak for the last 11 days, accumulating a total return of 51.75% during this period. Additionally, Integrated Proteins Ltd is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating strong momentum.<BR><BR>Despite these positive indicators, there are some concerns, such as a decrease in promoter holding to 2.23% and a significant drop in delivery volume, which fell by 86.69% against the 5-day average. However, the overall market-beating performance in both the long term and near term, alongside the stock's liquidity, suggests that the current rise is primarily driven by strong recent performance and investor interest.

Which are the latest news on Integ. Proteins?